Cécile Matthews

Vice President

Cécile Matthews is a vice president in the Life Sciences Practice and has 20 years of experience in strategy consulting for the life sciences industry.

Cécile Matthews leverages her expertise in pricing and market access to provide her clients with strategic insights on how to best prepare for launch and optimize revenues. Her areas of expertise include pricing, reimbursement, and market access on issues affecting biopharmaceuticals globally. She has deep experience working in oncology and rare diseases.

In oncology, Cécile has completed many assignments on i-os, targeted therapies, biosimilars, and companion diagnostics tackling issues such as early access, launch sequence, drivers of access, global pricing and access strategies, and launch readiness activities. In rare diseases, she has advised and published on issues such as early access, leveraging patient involvement, strategies to address uncertainty of evidence, and global pricing and market access strategies. She is particularly renowned for her expert knowledge of France.

Throughout her consulting career, Cécile has worked with clients on many aspects of the life science industry including biopharmaceuticals, medical devices, vaccines, and mobile health applications. Before joining CRA, Cécile was a principal at Eradigm Consulting, an insights and strategy consulting firm, and worked as an independent consultant and at Cambridge Pharma Consultancy/IMS Pricing and Reimbursement, now IQVIA.

Cécile is a dual French/British national.

Selected engagements

  • 01
    Long-term strategic partner in bladder cancer
    We formed a long-term, multi-project partnership with a leading manufacturer that was looking to establish its new product as standard of care in bladder...
    View engagement
  • 02
    Pricing and market access potential for doublet and triplet regimens in endometrial cancer
    CRA’s pricing and market access experts partnered with a global value and access team to develop the pricing and access strategy for novel combination...
    View engagement
  • 03
    CRA evaluates commercial efforts to develop a MS drug with respect to contractual obligations following merger
    CRA assessed commercial efforts to develop and commercialize a MS drug with respect to obligations stemming from the acquisition of Genzyme Corporation by...
    View engagement